Dihydropyrimidine dehydrogenase phenotype-guided dose individualization of fluoropyrimidine in gastrointestinal cancers: PRODIGE100-UCGI48-FUDOSE phase II study.

Fiche publication

Date publication

mai 2026

Journal

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BEN ABDELGHANI Meher , Pr BOUCHE Olivier , Pr LEPAGE Côme

Tous les auteurs :
Camilleri GM, Loriot MA, Teuff GL, Thuillier F, Bouche O, Narjoz C, Abdelghani MB, Herve C, Corbinais S, Locher C, Lecomte T, Villemin M, Tougeron D, Lepage C, Peytier A, Moussaddaq AS, Dubreuil O, Mabro M, Desrame J, Carvalho NS, Boige V

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42173726

Résumé

Pre-treatment screening for dihydropyrimidine dehydrogenase (DPD) deficiency based on plasma uracil concentration ([U]) is mandatory in France before fluoropyrimidine (FP) administration. However, dose-adjustment strategies according to [U] in case of partial DPD deficiency remain empirical, heterogeneous across centers and lacking clear recommendations.